Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Topigen Pharmaceuticals has initiated patient dosing in a Phase II safety and efficacy study in asthma with one of its lead product candidates, TPI ASM8.
Subscribe to our email newsletter
This study builds on prior pharmacodynamic and safety data in a three-day study of TPI ASM8 in an allergen challenge model and will be conducted in collaboration with leading clinical research centers across Europe, including the UK, Netherlands, France and Italy. TPI ASM8 is a novel, inhaled anti-inflammatory, RNA-targeting drug intended for the management of moderate to severe asthma.
The double-blind, randomized, placebo controlled crossover study in subjects with asthma will evaluate TPI ASM8 given once daily by inhalation in a breath-actuated inhaler over a 14-day period. TPI ASM8 acts primarily through inhibition of CCR3 and IL-5 receptors.
Mark Parry-Billings, chief development officer at Topigen, said: “TPI ASM8 is a truly innovative approach to the management of asthma and it is the first multi-targeted RNA antagonist to enter the clinic for the management of respiratory diseases.”